(Reuters) – Roivant Sciences and Pfizer Inc on Thursday announced the creation of a new unit to develop RVT-3101, the drugmakers’ treatment for ulcerative colitis.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Sherry Jacob-Phillips)
Roivant, Pfizer create unit for inflammatory disease drug
Dec 1, 2022 | 7:18 AM
